Domi Stickens

Chief Scientific Officer Arrakis Therapeutics Inc.

Domi is Vice President of Discovery and Translational Sciences at Arrakis Therapeutics. Domi has 20 years of drug discovery and translational research experience across multiple therapeutic areas in both large pharma and small biotechs. Prior to joining Arrakis, Domi was Head of Translational Sciences at Mitobridge, which was acquired by Astellas after initiation of several clinical stage programs. Previously, Domi was at Merck, where he held increasing roles of responsibility, leading programs from early discovery to clinical development across multiple therapeutic areas. His drug discovery experience includes therapeutic areas such as autoimmune diseases and inflammation, immuno-oncology, sarcopenia, urology and hematological disorders. Domi initiated his career in healthcare during his academic research, which focused on rare diseases, principally disorders of dysregulated bone development. Connecting with patients and patient advocacy groups catalyzed a long-term passion and career commitment to the advancement of treatments for diseases with a high unmet medical need. Domi received his BS degree in Biology from Antwerp University, Belgium and his PhD in developmental genetics from UTSW Medical Center, Dallas (TX). After his thesis research, he completed a postdoctoral fellowship with Zena Werb at UCSF in San Francisco, CA.

Seminars

Wednesday 11th November 2026
Restoring Splicing Function in DM1 by Selectively Targeting Toxic CUGRepeat RNA
4:30 pm
  • Selectively targeting toxic CUG-repeat RNA in DM1
  • Disrupting RNA foci to release MBNL1
  • Linking target engagement to restored splicing function
  • Building confidence in potency, selectivity and disease relevance
Thursday 12th November 2026
Panel Discussion: Target-Focused vs High-Throughput Approaches for Discovering Therapeutically Effective RNA-Targeting Small Molecules
9:00 am
  • What are the advantages and challenges associated with target-focused approaches?
  • What are the advantages and challenges associated with high-throughput phenotypic or cell-based functional screening approaches?
  • How is phenotypic RNA modulation connected back to a specific RNA target, binding site, or mechanism of action?
  • How does each approach manage generating actionable SAR and program attrition?
Domi Stickens